Mass spectrometry analyses of κ and λ fractions result in increased number of complementarity-determining region identifications

Proteomics

Volumn 12, Issue 2, 2012, Pages 183-191

  Broodman, Ingrid ^a   de Costa, Dominique ^a   Stingl, Christoph ^a   Dekker, Lennard J M ^a   Vanduijn, Martijn M ^a   Lindemans, Jan ^a   van Klaveren, Rob J ^a   Luider, Theo M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CDRs; Immunoglobulins; Kappa; Lambda; Lung cancer; Technology

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CIGARETTE SMOKING; CLINICAL ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ENZYME DEGRADATION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG ADENOCARCINOMA; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PURIFICATION;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; COMPLEMENTARITY DETERMINING REGIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SMOKING;

EID: 84855951084     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100244     Document Type: Article

References (36)

1. Lopes Pegna, A., Picozzi, G., Mascalchi, M., Maria Carozzi, F. et al., Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer 2009, 64, 34-40.
2. Infante, M., Lutman, F. R., Cavuto, S., Brambilla, G. et al., Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer 2008, 59, 355-363.
3. van Iersel, C. A., de Koning, H. J., Draisma, G., Mali, W. P. et al., Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int. J. Cancer 2007, 120, 868-874.
4. van Klaveren, R. J., Oudkerk, M., Prokop, M., Scholten, E. T. et al., Management of lung nodules detected by volume CT scanning. N. Engl. J. Med. 2009, 361, 2221-2229.
5. Reich, J. M., A critical appraisal of overdiagnosis: Estimates of its magnitude and implications for lung cancer screening. Thorax 2008, 63, 377-383.
6. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., Schreiber, R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
7. Dunn, G. P., Old, L. J., Schreiber, R. D., The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148.
8. Qiu, J., Hanash, S., Autoantibody profiling for cancer detection. Clin. Lab. Med. 2009, 29, 31-46.
9. Chen, G., Wang, X., Yu, J., Varambally, S. et al., Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res. 2007, 67, 3461-3467.
10. Qiu, J., Choi, G., Li, L., Wang, H. et al., Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. 2008, 26, 5060-5066.
11. Leidinger, P., Keller, A., Heisel, S., Ludwig, N. et al., Identification of lung cancer with high sensitivity and specificity by blood testing. Respir. Res. 2010, 11, 18.
12. Rom, W. N., Goldberg, J. D., Addrizzo-Harris, D., Watson, H. N. et al., Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer 2010, 10, 234.
13. Farlow, E. C., Patel, K., Basu, S., Lee, B. S. et al., Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 3452-3462.
14. Wu, L., Chang, W., Zhao, J., Yu, Y. et al., Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 3760-3768.
15. Zhong, L., Coe, S. P., Stromberg, A. J., Khattar, N. H. et al., Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol. 2006, 1, 513-519.
16. Chapman, C. J., Murray, A., McElveen, J. E., Sahin, U. et al., Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63, 228-233.
17. VanDuijn, M. M., Dekker, L. J., Zeneyedpour, L., Smitt, P. A., Luider, T. M., Immune responses are characterized by specific shared immunoglobulin peptides that can be detected by proteomic techniques. J. Biol. Chem. 2010, 285, 29247-29253.
18. Murphy, K. P., Travers, P., Walport, M. (Eds.), Janeway's Immunobiology, Garland Science, New York 2008.
19. Saada, R., Weinberger, M., Shahaf, G., Mehr, R., Models for antigen receptor gene rearrangement: CDR3 length. Immunol. Cell. Biol. 2007, 85, 323-332.
20. Andersen, P. S., Haahr-Hansen, M., Coljee, V. W., Hinnerfeldt, F. R. et al., Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. Mol. Immunol. 2007, 44, 412-422.
21. Baranzini, S. E., Jeong, M. C., Butunoi, C., Murray, R. S. et al., B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 1999, 163, 5133-5144.
22. Poulsen, T. R., Meijer, P. J., Jensen, A., Nielsen, L. S., Andersen, P. S., Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J. Immunol. 2007, 179, 3841-3850.
23. Weinstein, J. A., Jiang, N., White, R. A., 3rd, Fisher, D. S., Quake, S. R., High-throughput sequencing of the zebrafish antibody repertoire. Science 2009, 324, 807-810.
24. Annesley, T. M., Ion suppression in mass spectrometry. Clin. Chem. 2003, 49, 1041-1044.
25. de Costa, D., Broodman, I., Vanduijn, M. M., Stingl, C. et al., Sequencing and quantifying IgG fragments and antigen-binding regions by mass spectrometry. J. Proteome Res. 2010, 9, 2937-2945.
26. Chui, S. H., Lam, C. W., Lai, K. N., Light-chain ratios of immunoglobulins G, A, and M etermined by enzyme immunoassay. Clin. Chem. 1990, 36, 501-502.
27. Xu, J. L., Davis, M. M., Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 2000, 13, 37-45.
28. Chen, Z., Qiu, X., Gu, J., Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. Am. J. Pathol. 2009, 174, 1139-1148.
29. Eisenhardt, S. U., Schwarz, M., Schallner, N., Soosairajah, J. et al., Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents. Blood 2007, 109, 3521-3528.
30. Padlan, E. A., Abergel, C., Tipper, J. P., Identification of specificity-determining residues in antibodies. FASEB J. 1995, 9, 133-139.
31. Polonelli, L., Ponton, J., Elguezabal, N., Moragues, M. D. et al., Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One 2008, 3, e2371.
32. Geller, N. L., Pocock, S. J., Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 1987, 43, 213-223.
33. Olsen, J. V., Macek, B., Lange, O., Makarov, A. et al., Higher-energy C-trap dissociation for peptide modification analysis. Nat. Methods 2007, 4, 709-712.
34. Shen, Y., Tolic, N., Xie, F., Zhao, R. et al., Effectiveness of CID, HCD, and ETD with FT MS/MS for degradomic-peptidomic analysis: comparison of peptide identification methods. J. Proteome Res. 2011, 10, 3929-3943.
35. Dekker, L. J., Zeneyedpour, L., Brouwer, E., van Duijn, M. M. et al., An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions. Anal. Bioanal. Chem. 2011, 399, 1081-1091.
36. Boyd, S. D., Marshall, E. L., Merker, J. D., Maniar, J. M. et al., Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci. Transl. Med. 2009, 1, 12ra23.